Earnings season is off and running, and that means many golden opportunities to check in with the most important stocks in the health care industry.
With new U.S. health care policies going into effect, pressures from European austerity pressuring sales in the Old World, and large but often uncertain opportunities presented in developing markets, there's a lot of noise to distract investors from company-specific dynamics at work.
In the following video, health care bureau chief Brenton Flynn tries to cut through the noise and offers some of his key takeaways from last week's Stryker (NYSE: SYK ) earnings report.
One of Stryker's key competitors is a giant. In fact, in the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, critics think the company has spread itself too thin, becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand new premium report on Johnson & Johnson. To claim your copy simply click here now for instant access.